Follicular lymphoma: What innovations are available for liquid biopsy for FL

Liquid Biopsy Innovations for Follicular Lymphoma

TL;DR: Blood tests that detect cancer DNA are becoming available to monitor follicular lymphoma and catch recurrence earlier than traditional imaging, though most are still in research or early clinical use.

KEY POINTS:

• Molecular residual disease (MRD) testing uses blood to detect leftover cancer cells after treatment—potentially months before PET/CT scans show anything
• ctDNA tests (circulating tumor DNA) measure tiny pieces of cancer DNA floating in your bloodstream as a "liquid biopsy"
• The Foresight CLARITY Lymphoma test is the first ctDNA-MRD test included in NCCN Guidelines for B-Cell Lymphomas (December 2024)
• These tests can detect relapse approximately 6-7 months earlier than standard imaging in some lymphomas
• Most liquid biopsies are still in clinical trials or limited availability—ask your oncologist if you qualify for research studies

NEXT STEP:

Ask your oncologist: "Are there any liquid biopsy or MRD tests available for my follicular lymphoma, either through clinical trials or standard testing?"

---

[[FULL_ANSWER]]

What Are Liquid Biopsies?

A liquid biopsy is a blood test that detects cancer cells or cancer DNA in your bloodstream. Unlike traditional biopsies (which require removing tissue), liquid biopsies are non-invasive—just a simple blood draw.

For follicular lymphoma (FL), the most promising liquid biopsy innovation is molecular residual disease (MRD) testing, which looks for leftover cancer cells after treatment using circulating tumor DNA (ctDNA)—tiny fragments of cancer DNA floating in your blood.

How Does ctDNA Testing Work?

When cancer cells die (especially during treatment), they release DNA into the bloodstream. Modern blood tests can now detect this cancer DNA at extremely low levels—sometimes finding just a few cancer cells among billions of normal cells.

The clinical advantage: If MRD testing detects cancer DNA after treatment when you feel fine and imaging looks normal, it signals that cancer may be returning before symptoms appear. This "lead time" can be 6-7 months ahead of PET/CT imaging.

The Foresight CLARITY Lymphoma Test: Current Innovation

According to the NCCN Guidelines for B-Cell Lymphomas (December 2024), the Foresight CLARITY Lymphoma test (made by Natera) is now the first ctDNA-MRD test formally included in lymphoma treatment guidelines.

Key details about this test:

• What it detects: Uses a technology called PhasED-Seq to identify phased variants (specific DNA patterns) unique to your lymphoma cells
• Performance: In validation studies, it detected 90% of patients who later relapsed, compared to only 45% detected by standard PET/CT imaging at the same timepoint
• Sample: Simple blood/plasma draw
• Turnaround time: Results in approximately 8 days
• Current status: CLIA-certified laboratory test (not yet FDA-cleared); available through research trials and limited clinical ordering; broader clinical launch expected in 2026

How it's used clinically:

• Requires a prior tumor tissue sample (tumor-informed approach)
• Can be done at end of treatment to see if any cancer DNA remains
• Can be repeated during surveillance to catch early recurrence
• May help guide decisions about additional treatment or surveillance intensity

Other Liquid Biopsy Approaches in Development

Beyond the CLARITY test, researchers are exploring other ctDNA and MRD approaches for follicular lymphoma:

• Broader ctDNA panels that track multiple cancer mutations simultaneously
• Flow cytometry-based MRD that detects abnormal lymphoma cells in blood
• Integration with imaging: Using liquid biopsy results alongside PET/CT to make more informed treatment decisions

Clinical Trial Landscape

Several active clinical trials are testing liquid biopsy approaches in follicular lymphoma:

• ALPHA3 trial (NCT06500273): Testing MRD-guided treatment in LBCL patients post-remission
• SHORTEN-ctDNA trial (NCT06693830): Exploring whether ctDNA results can guide chemotherapy de-escalation (using less intensive treatment when ctDNA is negative)

These trials are investigating whether detecting MRD early can help oncologists make smarter treatment decisions—potentially avoiding unnecessary treatment for patients with no detectable disease, or intensifying treatment for those with early signs of recurrence.

Important Limitations & Current Reality

What you should know:

1. Not yet standard of care everywhere: While NCCN Guidelines now mention ctDNA-MRD testing, it's not yet universally available or covered by insurance. Most patients access it through clinical trials.

2. Requires baseline tumor sample: These tests need tissue from your original diagnosis to identify which specific mutations to track in your blood.

3. Research is ongoing: We're still learning how to best use these results to guide treatment decisions. A positive MRD test doesn't automatically mean you need more treatment—your doctor will consider the full clinical picture.

4. Cost and access: Reimbursement is not yet established. Availability varies by institution and clinical trial enrollment.

Questions to Ask Your Oncologist

Since liquid biopsy innovations are evolving rapidly, here are specific questions for your care team:

1. "Are there any liquid biopsy or MRD tests available for my follicular lymphoma—either through standard testing or clinical trials?"

2. "If I have MRD testing after my treatment ends, how would you use those results to guide my follow-up care?"

3. "Are there any clinical trials at your institution testing ctDNA or liquid biopsy approaches for FL?"

4. "Would liquid biopsy testing change my surveillance schedule or treatment decisions?"

5. "What is the cost, and would my insurance cover this testing?"

Bottom Line

Liquid biopsy innovations—particularly ctDNA-MRD testing—represent a significant advance in monitoring follicular lymphoma. The Foresight CLARITY Lymphoma test is now formally recognized in NCCN Guidelines and can detect recurrence months earlier than traditional imaging. However, most patients currently access these tests through clinical trials or specialized centers. As these technologies mature and become more widely available, they may transform how oncologists monitor FL and make treatment decisions.

According to the NCCN Guidelines for Patients: Follicular Lymphoma (2024), your care team uses multiple tools—imaging, blood tests, and increasingly, liquid biopsies—to track your disease and guide treatment. Ask your oncologist whether liquid biopsy testing is appropriate for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.